Millions of children at risk as vaccination uptake stalls
Progress in vaccinating children against a variety of life-threatening diseases has stalled in the past two decades - and even gone backwards in some countries - a new global study suggests.The situation has been made worse by the Covid pandemic, leaving millions of children unprotected from diseases such as measles, tuberculosis and polio. The researchers are calling for a concerted effort to provide better and more equal access to vaccines.Child health experts warn that cuts to international aid budgets that fund vaccination programmes, combined with vaccine scepticism, are creating a "perfect storm".
The global childhood vaccination programme has been a huge success.Since 1974, more than four billion children have been vaccinated, preventing an estimated 150 million deaths worldwide.In nearly half a century until 2023, researchers say vaccine coverage doubled.But since 2010 progress has stagnated, to the extent that there are now wide variations in vaccine coverage around the world.A study, published in the medical journal The Lancet, says measles vaccinations have declined in nearly 100 countries.The Covid-19 pandemic made things even worse, because of disruption to vaccine programmes during lockdowns.By 2023, there were nearly 16 million children who had not had any childhood vaccinations – most of them in sub-Saharan Africa and south Asia.Study author Dr Jonathan Mosser, from the Institute for Health Metrics and Evaluation at the University of Washington, in the United States, says large numbers of children remain under-vaccinated and un-vaccinated."Routine childhood vaccinations are among the most powerful and cost-effective public health interventions available, but persistent global inequalities, challenges from the Covid pandemic, and the growth of vaccine misinformation and hesitancy have all contributed to faltering immunisation progress," he said.Dr Mosser said there was now increased the risk of outbreaks of diseases such as measles, polio and diphtheria.All children should benefit from life-saving immunisations, he added.Wide discrepancies remain between vaccination rates in wealthier and lower-income countries.But the report's authors warn that vaccination rates have fallen in Europe, the US and other wealthy countries too.
Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, says the findings present a concerning picture."More children will be hospitalised, permanently damaged and die from fully preventable diseases if the trend is not reversed."Alas, the cuts in global health funding mean that this situation is set to deteriorate," Prof Pollard said.Dr David Elliman, from University College London, says many factors have contributed to the current situation."Around the world, the increasing number of countries torn apart by civil unrest and wars, combined with the drastic cuts in foreign aid from rich nations, such as USA and UK, makes it difficult to get vaccines to many populations," he said."Where it appears that policy is being made on the basis of ill-informed opinion, rather than science, we have a perfect storm," Dr Elliman added.The researchers recommend that all countries try to strengthen primary healthcare systems and combat misinformation around vaccines to prevent parents being hesitant about getting their children vaccinated.They also call for a concerted effort to provide better and more equal access to vaccines around the world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
15 minutes ago
- The Independent
Kennedy's new vaccine advisers meet for first time
U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers began their first meeting Wednesday under intense scrutiny from medical experts worried about Americans' access to lifesaving shots. First on the agenda is an awkward scenario: Kennedy already announced COVID-19 vaccines will no longer be recommended for healthy children or pregnant women, and his new advisers aren't scheduled to vote on whether they agree. Yet government scientists prepared meeting materials calling vaccination 'the best protection' during pregnancy — and said most children hospitalized for COVID-19 over the past year were unvaccinated. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months who could have some protection if their mom got vaccinated during pregnancy, according to the CDC's presentation. It's one signal that this week's two-day meeting of the Advisory Committee on Immunization Practices isn't business as usual. Another sign: Shortly before the meeting, a Virginia-based obstetrician and gynecologist stepped down from the committee, bringing the panel's number to just seven. The Trump administration said Dr. Michael Ross withdrew during a customary review of members' financial holdings. The meeting opened as the American Academy of Pediatrics announced that it will continue publishing its own vaccine schedule for children but now will do so independently of the ACIP, calling it 'no longer a credible process.' The panel, created more than 60 years ago, helps the CDC determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available, such as at pharmacies. Earlier this month, Kennedy abruptly dismissed the existing 17-member expert panel and handpicked eight replacements, including several anti-vaccine voices. And a number of the CDC's top vaccine scientists — including some who lead the reporting of data and the vetting of presentations at ACIP meetings — have resigned or been moved out of previous positions. The highly unusual moves prompted a last-minute plea from a prominent Republican senator to delay this week's meeting. Sen. Bill Cassidy of Louisiana, a physician who chairs the chamber's health committee, said Monday that many of Kennedy's chosen panelists lack the required expertise and 'may even have a preconceived bias' against new vaccine technologies. In a House hearing Tuesday, Kennedy defended his purge, saying the old panel had been 'a template for medical malpractice.' Rep. Kim Schrier, a pediatrician and Democrat from Washington state, told Kennedy: 'I will lay all responsibility for every death from a vaccine-preventable illness at your feet.' Committee will vote on RSV protections The two-day meeting's agenda on was abruptly changed last week. Discussion of COVID-19 shots will open the session on Wednesday. Later in the day, the committee will take up RSV, with votes expected. On Thursday, the committee will vote on fall flu vaccinations and on the use of a preservative in certain flu shots. RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms that can be dangerous for infants. In 2023, U.S. health officials began recommending two new measures to protect infants — a lab-made antibody for newborns and a vaccine for pregnant women — that experts say likely drove an improvement in infant mortality. The committee will discuss another company's newly approved antibody shot, but the exact language for the vote was not released prior to the meeting. 'I think there may be a theme of soft-pedaling or withdrawing recommendations for healthy pregnant women and healthy children,' even though they are at risk from vaccine-preventable diseases, said Lawrence Gostin, a public health law expert at Georgetown University who co-authored a recent medical journal commentary criticizing the COVID-19 vaccination decision. Flu shot recommendations to be debated At its June meetings, the committee usually refreshes guidance for Americans 6 month and older to get a flu shot, and helps greenlight the annual fall vaccination campaign. But given the recent changes to the committee and federal public health leadership, it's unclear how routine topics will be treated, said Jason Schwartz, a Yale University health policy researcher who has studied the committee. Thursday also promises controversy. The advisory panel is set to consider a preservative in a subset of flu shots that Kennedy and some antivaccine groups have falsely contended is tied to autism. In preparation, the CDC posted a new report confirming that research shows no link between the preservative, thimerosal, and autism or any other neurodevelopmental disorders. Gostin said the agenda appears to be 'a combination of what we would normally expect ACIP to cover along with a mixture of potential conspiracy theories,' he said. 'We clearly are in a new normal that's highly skeptical of vaccine science.' The committee's recommendations traditionally go to the Centers for Disease Control and Prevention director. Historically, nearly all are accepted and then used by insurance companies in deciding what vaccines to cover. But the CDC currently has no director, so the committee's recommendations have been going to Kennedy, and he has yet to act on a couple recommendations ACIP made in April. The CDC director nominee, Susan Monarez, is slated to go before a Senate committee on Wednesday. ___ Neergaard reported from Washington. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
The Independent
an hour ago
- The Independent
Invasive cancer tests could be dropped for new ‘sponge' method
Thousands of individuals currently monitored for food pipe cancer could be spared invasive diagnostic procedures thanks to a groundbreaking "sponge on a string" test, new research suggests. A study published in The Lancet medical journal indicates that this less invasive method could replace traditional endoscopies for more than half of patients with Barrett's oesophagus, a condition where stomach acid damages the lining of the food pipe, potentially leading to oesophageal cancer. Currently, the NHS offers regular monitoring for Barrett's oesophagus every two to five years, involving an endoscopy where a camera-equipped tube is passed into the oesophagus. This procedure, while effective, is invasive and can be uncomfortable for patients. However, researchers believe a new, less invasive capsule sponge test could offer a viable alternative for many. Already in use in some NHS hospitals for diagnosis, the test involves a patient swallowing a capsule attached to a string. Once swallowed, the capsule dissolves in the stomach, leaving a small sponge. After a few minutes, NHS staff pull the sponge back out via the string, collecting cells from the oesophageal lining for analysis. The new Lancet study, funded by Cancer Research UK, NHS England Cancer Alliance, and Innovate UK, involved 910 participants across 13 UK hospitals. The findings revealed that approximately 15 per cent of patients were identified as being at high risk of developing cancer, while 54 per cent were classified as low risk. The study's authors concluded that the capsule sponge could effectively monitor patients with low-risk Barrett's oesophagus, replacing the need for regular endoscopies. Crucially, the test could be administered by nurses in GP practices, making it more accessible. Professor Peter Sasieni from Cancer Research UK's cancer prevention trials unit at Queen Mary University of London commented: "Our findings suggest that the capsule sponge could help stratify patients with Barrett's oesophagus by risk and that half of them will fall into the low-risk group. 'Given that the risk of these individuals progressing to dysplasia (abnormal cells) and then to oesophageal cancer is so low, it should be safe to replace their usual endoscopy with the capsule sponge." Professor Rebecca Fitzgerald from Cambridge added: "We are very excited by these results, which could lead to a test that is much more accessible and less operator dependent to improve standards for monitoring for patients with Barrett's across the NHS and beyond." Michelle Mitchell, chief executive of Cancer Research UK, also remarked on the breakthrough: "Survival rates for oesophageal cancer have remained unacceptably low for decades, with fewer than 20 per cent of patients surviving for five or more years after diagnosis. Early detection is vital if we are to change this grim statistic." Ms Mitchell hailed the capsule sponge as "one of the most promising breakthroughs in early detection we have seen to date," adding that these new findings bring us closer to transforming diagnosis and treatment. "If adopted widely, this innovative approach could spare significant numbers of people from discomfort and invasive endoscopies. By bringing this more accessible alternative into community care, we have the potential to save more lives."
Reuters
7 hours ago
- Reuters
Bharat, GSK to halve price of malaria vaccine by 2028
LONDON, June 25 (Reuters) - Drugmakers Bharat Biotech and GSK (GSK.L), opens new tab will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said, opens new tab it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose.
